Advertisement

Topics

FDA Approves First Biomarker-Driven Drug for HCC

11:54 EDT 13 May 2019 | Medscape

Ramucirumab is for the treatment of hepatocellular carcinoma in patients with an alpha-fetoprotein level of 400 ng/mL or higher.
FDA Approvals

Original Article: FDA Approves First Biomarker-Driven Drug for HCC

NEXT ARTICLE

More From BioPortfolio on "FDA Approves First Biomarker-Driven Drug for HCC"

Advertisement
Quick Search
Advertisement
Advertisement